Key Insights

Highlights

Success Rate

58% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 67/100

Termination Rate

29.6%

8 terminated out of 27 trials

Success Rate

57.9%

-28.6% vs benchmark

Late-Stage Pipeline

41%

11 trials in Phase 3/4

Results Transparency

64%

7 of 11 completed with results

Key Signals

7 with results58% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (5)
P 2 (8)
P 3 (11)

Trial Status

Completed11
Terminated8
Recruiting3
Not Yet Recruiting2
Unknown2
Withdrawn1

Trial Success Rate

57.9%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT01501643Not ApplicableTerminated

Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease

NCT01891812Phase 2Completed

Nitrous Oxide Analgesia Vaso-occlusive Crisis

NCT03412045Not ApplicableCompletedPrimary

Hyperbaric Oxygen Therapy in Sickle Cell Pain

NCT05348915Phase 3Terminated

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

NCT04935879Phase 3Completed

A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

NCT05378555Phase 3RecruitingPrimary

Oral Ketamine for Treatment of Vaso-Occlusive Pain

NCT07200869Not Yet Recruiting

Outcomes of Vaso-occlusive Crisis in Pediatric Sickle Cell Disease

NCT03353584Not ApplicableRecruiting

Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease

NCT06345638Completed

Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease

NCT04927247Phase 3Terminated

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

NCT04150757Phase 3Terminated

Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED

NCT06181695Phase 3Not Yet RecruitingPrimary

Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric

NCT05289700Phase 3Unknown

Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD)

NCT05376046Recruiting

Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)

NCT04756375Not ApplicableCompletedPrimary

Evaluation of Virtual Reality to Save Morphinic in the Treatment of Vaso-occlusive Seizures of Sickle Cell Patients Consulting in the Emergency Room

NCT03296345Phase 2Completed

Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis

NCT02433158Phase 3Terminated

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

NCT04301336Phase 2CompletedPrimary

Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia

NCT00263562Phase 3Terminated

Steroid Treatment for Sickle Cell Pain Crisis

NCT01119833Phase 2Completed

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

Scroll to load more

Research Network

Activity Timeline